Tong Dai, MD: Considering all the options, it looks like if the patient needs faster response, pembrolizumab plus lenvatinib ...
Efficacy data remain consistent with prior disclosure and continue to demonstrate broad and deep PSA responses, with 55% PSA50 response rate and ...
In an interview with Targeted Oncology at the 2025 North American Neuroendocrine Tumor Society (NANETS) Symposium, Michael ...
We show that, compared with surgeon predictions and existing risk-prediction tools, our machine-learning model can enhance ...
Among people in prison, adding CXR or CRP to symptom screen was more effective than symptom screen alone. In addition to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback